BCMA expression (target of teclistamab / elranatamab / cilta-cel / ide-cel)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

ID	`BIO-BCMA-EXPRESSION`
Type	Biomarker
Aliases	BCMA expressionЕкспресія BCMA (мішень теклістамабу / елранатамабу / cilta-cel / ide-cel)
Status	reviewed 2026-04-29 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-CARTITUDE-1-BERDEJA-2021` `SRC-MAJESTEC-1-MOREAU-2022` `SRC-NCCN-MM-2025`

Biomarker Facts

Biomarker type	protein_expression_ihc
Measurement	MethodIHC on BM core biopsy or flow cytometry on plasma cells (anti-BCMA / anti-TNFRSF17) Unitscategorical (positive \| negative); semi-quantitative %
Related biomarkers	None declared

Notes

BCMA (B-cell maturation antigen, encoded by TNFRSF17) is universally expressed on malignant plasma cells in multiple myeloma — therapeutic target for the entire BCMA-directed class: - **BCMA × CD3 bispecifics**: teclistamab (MajesTEC-1, ORR 63% / ≥CR 39% in penta-refractory MM); elranatamab (MagnetisMM-3 — pivotal trial for elranatamab; SRC entry NOT YET INGESTED, flagged in commit body). - **BCMA CAR-T**: ciltacabtagene autoleucel (CARTITUDE-1, ORR 97% / sCR 67% in heavily pre-treated R/R MM); idecabtagene vicleucel (KarMMa, R/R MM). - **BCMA ADC**: belantamab mafodotin (DREAMM-7/8, R/R MM). Cross-disease relevance: MM is the only adult disease with BCMA-directed therapy in clinical use. BCMA+ status is assumed by histology (plasma-cell neoplasm) in clinical trials — formal IHC/flow measurement not part of standard MM workup but documented in trial eligibility logs and as reference for BCMA-loss / antigen-escape surveillance at relapse on BCMA-directed therapy. Quantitative measurement gains relevance at relapse: BCMA-loss / low expression after prior BCMA therapy is an emerging mechanism of resistance — IHC re-biopsy can guide re-treatment vs class switch (talquetamab / GPRC5D,...

Used By

No reverse references found in the YAML corpus.